Menu
Menu
Emeritus Professor of the Universitat Autònoma de Barcelona; Biomedical Research Institute-SPau, and Hospital Sant Pau, CIBERER UNIT 747; Mas Casanova, Barcelona, Spain
Dr. Susan M. Webb is Emeritus Professor of Medicine at the Autonomous University of Barcelona and Honorary Senior Consultant Endocrinologist at Hospital Sant Pau, Barcelona, Spain where she created the Neuroendocrine Clinic; her research group on Pituitary Diseases is part of the Spanish Network of Excellence of Rare Diseases (CIBERER Unit 747). She is interested in the long-term consequences of pituitary diseases and evaluation of health-related quality of life.
Dr. Webb earned her medical degree from the University of Barcelona Medical School and completed her residency in endocrinology at the Hospital Clinic in Barcelona, Spain. She undertook her Clinical Research Fellowship at St. Bartholomew’s Hospital, London, UK, and was a Fulbright Scholar for Reproductive Neuroendocrinology in San Antonio, Texas, USA during the period 1983-1984.
Dr Webb coordinates the European Registry on Cushing’s Syndrome (ERCUSYN), initially financed by the European Union 2007̶ 2010, which includes data from over 2000 patients. She has been President of the Spanish Society of Endocrinology and Nutrition, Secretary of the European Neuroendocrine Association and, until 2018, a member of the Executive Committee of the European Society of Endocrinology.
Dr Webb has been an editorial board member for The Journal of Clinical Endocrinology & Metabolism, Pituitary, Endocrine, Medicina Clínica and Endocrinología, Nutrición y Diabetes, among other journals. She has been a member of the European Union Committee of Experts on Rare Diseases (EUCERD), and is currently Scientific Deputy Director of CIBERER and President of the Rare Diseases Advisory Committee of the Catalan health system, CatSalut. She has supervised more than 20 doctoral theses and has co-authored more than 400 publications. In 2019, the group she was leading was designated a reference center for pituitary diseases (CSUR – centro, servicio o unidad de referencia) by the Spanish Ministry of Health which, in 2022, became part of the European Network for Rare Diseases (RareEndoERN). She has extensive clinical experience in neuroendocrine disorders, has been in receipt of over 40 grants, and has served as the principal investigator of numerous clinical trials.
Dr Webb has received awards for teaching and clinical investigation from the European Society of Endocrinology (Clinical Endocrinology Trust Award, 2019) and the European Neuroendocrine Association (Rolf Gaillard Award, 2019).
Disclosures: Dr Webb is on the Scientific Advisory Boards of Novartis, Ipsen, Recordati Rare Diseases and HRA Pharma Rare Diseases. She has received speaker fees from Ipsen, HRA Pharma Rare Diseases, Recordati Rare Diseases and Consilient Health. Dr Webb has received unrestricted research funds from Pfizer and HRA Pharma Rare Diseases and has assisted with clinical trials for Novartis, Recordati Rare Diseases and Cortendo.
Associate Professor of Endocrinology, Department of Biotechnology and Translational Medicine, University of Milan, and Director of Endocrinology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Iacopo Chiodini’s research career commenced in 1994, since which he has largely focused on the influence of endocrine disorders on bone metabolism, particularly in relation to overt and subclinical hypercortisolism. He is currently focusing on the diagnosis and therapy of subclinical hypercortisolism, the role of cortisol secretion in hypertension, diabetes and osteoporosis, and the involvement of bone in metabolic syndrome.
Iacopo Chiodini is co-author of more than 170 peer-reviewed papers (Scopus h-index 44). He has coordinated several studies on the effects of subclinical hypercortisolism in patients with adrenal incidentalomas, the role of the hypothalamic-pituitary-adrenal axis, and individual sensitivity to glucocorticoid excess in patients with diabetes and osteoporosis, as well as the effects of conservative or surgical approaches to treatment in patients with mild hypercortisolism. He is currently involved with several drug-development trials for the treatment of both overt and subclinical hypercortisolism and is a member of advisory boards that focus on hypercortisolism screening in high-risk populations.
Iacopo Chiodini has been speaker, or Chair, at more than 130 national and international meetings and Visiting Professor for subclinical hypercortisolism and adrenal incidentalomas at several renowned US institutions. These include the University of Central Florida, Orlando, FL; University of Michigan, Ann Arbor, MI; University of Arizona, Phoenix, AZ; Oregon Health & Science University, Portland, OR; University of California, Sacramento and San Diego, CA; Johns Hopkins Hospital, Baltimore, MD; Mount Sinai Hospital, New York, NY; and the Medical College of Wisconsin, Milwaukee, WI.
Iacopo Chiodini is Editor-in-Chief of the journal section Adrenal Endocrinology in Frontiers in Endocrinology and a member of the adrenal incidentaloma study group of ENS@T (the European Network for the Study of Adrenal Tumors). He is current President of the Italian Society for Osteoporosis and Metabolic Bone Diseases.
Disclosures: Iacopo Chiodini has served on advisory boards for HRA Pharma Rare Diseases, Corcept Therapeutics, Eli-Lilly, Amgen, UCB, Abiogen, Theramex, and Sandoz and is currently involved with clinical trials for HRA Pharma Rare Diseases, and Corcept Therapeutics.
Associate Professor, Division of Endocrinology, Metabolism, Diabetes and Nutrition, and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Dr Irina Bancos works in the Pituitary-Adrenal-Gonadal subdivision of the Mayo Clinic, Rochester, USA where she also serves as the Associate Program Director for the Endocrine Fellowship. She received her M.D. from the Iuliu Hatieganu Medical University in Cluj-Napoca, Romania and completed her Internal Medicine Residency at Danbury Hospital in CT, USA and Endocrinology Fellowship at the Mayo Clinic, Rochester.
Dr Bancos completed a two-year research fellowship (Mayo Foundation Scholarship) at the University of Birmingham, UK, where she received training in steroid profiling and adrenal disorders. In 2015, she returned to the Mayo Clinic where her clinical and research interests now include adrenal and pituitary tumors, pheochromocytoma/paraganglioma, primary aldosteronism, adrenal insufficiency, congenital adrenal hyperplasia, Cushing syndrome, and mechanisms of steroid regulation of health and disease.
From 2015-2018, Dr Bancos was the Principal Investigator and Leader of the ‘Transform the Adrenal Practice Team’ at the Mayo Clinic. She is currently leading a longitudinal-observational study with the aim of characterizing the clinical course, glucocorticoid withdrawal, quality-of-life, and metabolic outcomes of patients with mild and overt hypercortisolism.
Dr. Bancos holds several grants in the field of adrenal disorders and is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute on Aging (NIA), in addition to several internal, benefactor, and industry awards. Dr Bancos has published more than 180 scientific articles and has served on several editorial boards for the Journal of Clinical Endocrinology and Metabolism and Endocrine Practice; she currently serves as Associate Adrenal Editor for the European Journal of Endocrinology. She is passionate about translating research findings into actionable interventions for patients and mentoring the future generation of adrenal endocrinologists.
Disclosures: Dr Irina Bancos has served on scientific advisory boards for Neurocrine Biosciences, Diurnal®, Spruce Biosciences Inc, Sparrow, Corcept Therapeutics Inc, HRA Pharma Rare Diseases, and Recordati Rare Diseases (fee to institution). She has received institutional funding from the NIH, NIA, NIDDK, and Recordati Rare Diseases (investigator initiated award), as well as family benefactor funding via receipt of the Olin Award. She has also received funding to the institution from her work as Principal Investigator in trials sponsored by Corcept Therapeutics Inc, Neurocrine Biosciences, Spruce Biosciences Inc, Sparrow, Diurnal®, CinCor Pharma Inc, and Ascendis. She has received fees payable to her institution from her membership of the Data Safety Monitoring Board at Adrenas. Dr Bancos has also edited adrenal topics for DynaMed and written on the same topic for Elsevier.
Senior Clinical Lecturer in Endocrinology and Honorary Consultant Endocrinologist. Institute of Metabolism and Systems Research (IMSR), College of Medical and Dental Sciences, University of Birmingham; Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, UK
